方盛制药：控股子公司中药创新药研发项目获得药物临床试验批准通知书

Group 1 - The core point of the article is that Fangsheng Pharmaceutical's subsidiary, Fangsheng R&D, has received approval from the National Medical Products Administration for the clinical trial of its innovative traditional Chinese medicine, Ziying Granules [1] - Ziying Granules is classified as a Class 1 innovative traditional Chinese medicine and has not yet been launched in domestic or international markets as of the announcement date [1] - The product is developed based on years of clinical experience in treating pelvic inflammatory disease and is specifically aimed at alleviating chronic pelvic pain associated with pelvic inflammatory disease sequelae [1]